Aerovate Therapeutics, Inc.
AVTE
$2.68
-$0.04-1.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 66.56% | 34.46% | -6.85% | -13.58% | -4.34% |
| Total Depreciation and Amortization | -96.33% | 678.57% | 0.00% | 0.00% | 12.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.58% | -51.40% | -7.79% | 48.83% | -4.82% |
| Change in Net Operating Assets | -333.46% | -237.25% | 128.84% | -220.87% | 118.49% |
| Cash from Operations | 31.14% | 21.48% | 13.69% | -59.95% | 5.20% |
| Capital Expenditure | -- | -- | -- | -- | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.29% | -10.74% | 103.78% | 54.64% | 143.61% |
| Cash from Investing | -18.29% | -10.74% | 103.78% | 56.39% | 143.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,418.18% | -99.91% | 3,373.58% | 52.05% | 387.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 68.24% | -- | 100.00% |
| Cash from Financing | 2,418.18% | -99.91% | 5,076.22% | 1.73% | 2,215.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5,630.43% | -99.79% | 252.74% | -65.37% | 69.75% |